After the FDA Webcast: Discussing Clinical Endpoints

S2 E5.2 – After the FDA Webcast: Discussing Clinical Endpoints

The Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of theFDA Webcast that centered on clinical and surrogate endpoints
()

The panel discussed key takeaways from the FDA webcast on NASH Drug Development on the subject of endpoints. The group focused discussion on a few issues: (a) histology, both in terms of its continued primacy as a surrogate for pre-cirrhotics and FDA’s willingness to accept digital histology; (b) ratification that “the goal posts” are not moving on the endpoint issue; (c) frank statement that risk:benefit ratio will shape how the agency evaluates drug candidates; and (d) histopath adjudication.

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript
First
Last

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"